89bio Reports Positive Topline Results from an Expansion Cohort of the Phase Ib/IIa Trial of Pegozafermin (BIO89-100) for the Treatment of NASH

89bio, Inc. announced positive topline results from an open-label expansion cohort of 20 patients in the Phase Ib/IIa proof-of-concept study evaluating pegozafermin for the treatment of non-alcoholic steatohepatitis (NASH).